New data on lecanemab presented at the CTAD Alzheimer conference

Stockholm, November 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and partner Eisai held several oral presentations at the 14 th Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021, revealing new data on lecanemab (BAN2401), an investigational anti-amyloid beta protofibril antibody. The presentations provided further support for the encouraging data regarding lecanemab’s potential as a treatment for early Alzheimer’s disease previously seen in the Phase 2b as well as open label extension study. In addition, data presented showed the potential to use blood tests with p-tau181 and Aβ42/40 to monitor treatment effect of lecanemab. Data presented also clarified similarities and differences in the binding profiles of lecanemab compared to other late-stage anti-amyloid antibodies for Alzheimer’s disease.

The release as fetched from its publisher. bioarctic.com ↗